Proscan RX Pharma Inc.
Records under this name other than patents Proscan RX Pharma Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Proscan RX Pharma Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,910,693 | Prostate cancer diagnosis and treatment Lapsed on the fee record Ended Mar 22, 2023 · From the USPTO record | Lapsed on the fee record | Ended Mar 22, 2023 | From the USPTO record |
| US 7,811,564 | Prostate cancer diagnosis and treatment Lapsed on the fee record Ended Oct 12, 2022 · From the USPTO record | Lapsed on the fee record | Ended Oct 12, 2022 | From the USPTO record |
| US 8,629,247 | Antibodies against prostate specific membrane antigen Lapsed on the fee record Ended Jan 14, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jan 14, 2022 | From the USPTO record |
| US 8,512,702 | Prostate cancer diagnosis and treatment Lapsed on the fee record Ended Aug 20, 2021 · From the USPTO record | Lapsed on the fee record | Ended Aug 20, 2021 | From the USPTO record |
| US 8,101,713 | Prostate cancer diagnosis and treatment Lapsed on the fee record Ended Jan 24, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jan 24, 2020 | From the USPTO record |